Rosansky SJ - Search Results

1

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM. Moe SM, et al. Among authors: rosansky sj. Nephrol Dial Transplant. 2005 Oct;20(10):2186-93. doi: 10.1093/ndt/gfh966. Epub 2005 Jul 19. Nephrol Dial Transplant. 2005. PMID: 16030053 Clinical Trial.

2

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA. Quarles LD, et al. Among authors: rosansky sj. J Am Soc Nephrol. 2003 Mar;14(3):575-83. doi: 10.1097/01.asn.0000050224.03126.ad. J Am Soc Nephrol. 2003. PMID: 12595492 Clinical Trial.

3

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. EVOLVE Trial Investigators, et al. N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121374 Free article. Clinical Trial.

4

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Coyne D, et al. Am J Kidney Dis. 2006 Feb;47(2):263-76. doi: 10.1053/j.ajkd.2005.10.007. Am J Kidney Dis. 2006. PMID: 16431255 Clinical Trial.

5

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U; RUBRA Study Investigators. Spinowitz B, et al. Am J Nephrol. 2008;28(2):280-9. doi: 10.1159/000111115. Epub 2007 Nov 13. Am J Nephrol. 2008. PMID: 18004064 Clinical Trial.

6

Use of transdermal clonidine in chronic hemodialysis patients.

Rosansky SJ, Johnson KL, McConnell J. Rosansky SJ, et al. Clin Nephrol. 1993 Jan;39(1):32-6. Clin Nephrol. 1993. PMID: 8428405

7

Rate of change of end-stage renal disease treatment incidence 1978-1987--has there been selection?

Rosansky SJ, Jackson K. Rosansky SJ, et al. J Am Soc Nephrol. 1992 Apr;2(10):1502-6. doi: 10.1681/ASN.V2101502. J Am Soc Nephrol. 1992. PMID: 1600122

8

Has the yearly increase in the renal replacement therapy population ended?

Rosansky SJ, Clark WF. Rosansky SJ, et al. J Am Soc Nephrol. 2013 Sep;24(9):1367-70. doi: 10.1681/ASN.2013050458. Epub 2013 Jul 18. J Am Soc Nephrol. 2013. PMID: 23868925 Free PMC article.

9

Comparative incidence rates of end-stage renal disease treatment by state.

Rosansky SJ, Huntsberger TL, Jackson K, Eggers P. Rosansky SJ, et al. Am J Nephrol. 1990;10(3):198-204. doi: 10.1159/000168081. Am J Nephrol. 1990. PMID: 2382681

10

Early start of dialysis: a critical review.

Rosansky S, Glassock RJ, Clark WF. Rosansky S, et al. Clin J Am Soc Nephrol. 2011 May;6(5):1222-8. doi: 10.2215/CJN.09301010. Clin J Am Soc Nephrol. 2011. PMID: 21555505 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page